See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $250B | 3.9x | 9.3x | |
| $206B | 3.2x | 8.5x | |
| $146B | 3.1x | 10.8x | |
| $90.8B | 2.3x | 6.5x | |
| $37.9B | 6.1x | 23.4x | |
| $11.6B | 4.2x | -10.1x | |
| $11.3B | 30.2x | 98.7x | |
| $9.6B | 2.4x | 17.5x | |
| $7.8B | n/a | -14.1x | |
| $7.4B | 2.4x | -2.0x | |
| $5.0B | 6.3x | 24.3x | |
| $4.6B | 10.8x | 36.2x | |
| $3.9B | 5.4x | 14.0x | |
| $3.1B | 82.1x | n/a | |
| $2.7B | n/a | n/a | |
| $2.7B | 6.3x | 22.1x | |
| $2.3B | 5.5x | 20.7x | |
| $1.9B | n/a | n/a | |
| $1.8B | 8.8x | -27.0x | |
| $1.7B | 14.6x | -23.1x | |
| $1.6B | 2.1x | 7.2x | |
| $1.4B | n/a | n/a | |
| $1.3B | n/a | n/a | |
| $1.3B | 5.6x | 20.2x | |
| $1.2B | 4.2x | 25.2x | |
| $1.1B | 6.3x | n/a | |
| $1.1B | n/a | n/a | |
| $947M | n/a | n/a | |
| $920M | 3.9x | 10.6x | |
| $826M | 4.1x | 14.3x | |
| $737M | 115.6x | -3.8x | |
| $724M | 5.3x | 10.3x | |
| $686M | 3.5x | 19.3x | |
| $630M | n/a | n/a | |
| $630M | n/a | n/a | |
| $620M | n/a | n/a | |
| $616M | 199.6x | -2.8x | |
| $604M | 0.9x | -2.7x | |
| $569M | 68.0x | -2.2x | |
| $517M | n/a | -14.5x | |
| $516M | 8.2x | -0.9x | |
| $510M | n/a | n/a | |
| $444M | n/a | n/a | |
| $433M | n/a | n/a | |
| $430M | 21.6x | 92.3x | |
| $422M | 5.5x | -15.5x | |
| $392M | n/a | n/a | |
| $382M | 2.3x | 10.8x | |
| $378M | n/a | n/a | |
| $327M | 6.3x | -92.2x | |
| $316M | n/a | n/a | |
| $297M | 1.2x | -3.5x | |
| $290M | 8.3x | n/a | |
| $274M | 177.1x | -5.1x | |
| $255M | n/a | n/a | |
| $249M | 10282.8x | -0.9x | |
| $228M | 2031.1x | n/a | |
| $223M | n/a | n/a | |
| $221M | n/a | -8.4x | |
| $209M | 100.0x | -2.5x | |
| $202M | 0.4x | 1.1x | |
| $201M | n/a | n/a | |
| $179M | n/a | n/a | |
| $166M | 53.6x | n/a | |
| $160M | 26697.8x | n/a | |
| $152M | 2.9x | -1.0x | |
| $152M | n/a | n/a | |
| $149M | n/a | n/a | |
| $134M | 32670.7x | n/a | |
| $133M | 0.5x | -0.4x | |
| $124M | 1.3x | 2.1x | |
| $124M | 78.4x | -1.5x | |
| $123M | 30.4x | n/a | |
| $122M | 21.1x | -7.6x | |
| $122M | 3.5x | n/a | |
| $122M | n/a | n/a | |
| $112M | 26.1x | n/a | |
| $112M | 1.0x | n/a | |
| $110M | n/a | n/a | |
| $109M | n/a | n/a | |
| $104M | 2.2x | -0.6x | |
| $103M | n/a | n/a | |
| $91.1M | 2.6x | -2.0x | |
| $86.6M | 2.3x | n/a | |
| $86.4M | n/a | n/a | |
| $83.0M | 6.2x | -3.0x | |
| $79.5M | n/a | n/a | |
| $64.7M | 0.6x | -0.9x | |
| $60.7M | 6.4x | n/a | |
| $59.5M | 9.9x | -3.8x | |
| $45.2M | n/a | n/a | |
| $42.2M | n/a | n/a | |
| $38.3M | n/a | n/a | |
| $35.7M | 0.4x | -0.2x | |
| $31.6M | 0.2x | -0.7x | |
| $31.0M | n/a | n/a | |
| $31.0M | n/a | n/a | |
| $30.1M | 16.1x | -1.3x | |
| $28.9M | 3.2x | n/a | |
| $25.0M | n/a | -0.6x | |
| $23.7M | 0.2x | -0.4x | |
| $16.3M | 2.6x | -0.4x | |
| $14.8M | 1.5x | -1.2x | |
| $14.3M | 2.2x | n/a | |
| $8.3M | 17.0x | n/a | |
| $7.0M | 0.0x | -0.1x | |
| $4.5M | 1.9x | n/a | |
| -$1.8M | n/a | n/a | |
| -$1.8M | -0.2x | n/a | |
| -$4.8M | -0.2x | n/a | |
| -$5.7M | n/a | 0.1x | |
| -$6.8M | -0.5x | 0.1x | |
| -$9.1M | -7.3x | n/a | |
| -$16.9M | -2.1x | n/a | |
| -$21.0M | -4.1x | 0.3x | |
| -$23.1M | n/a | 0.3x | |
| -$24.3M | -12.3x | 0.4x | |
| -$35.0M | -0.9x | 0.7x | |
| -$36.2M | -3.0x | 0.2x | |
| -$40.3M | -166.4x | n/a | |
| -$44.2M | n/a | n/a | |
| -$44.6M | -11.4x | 0.8x | |
| -$45.9M | -0.4x | 3.7x | |
| -$49.7M | n/a | n/a | |
| -$52.8M | -6.2x | n/a | |
| -$52.9M | n/a | 0.4x | |
| -$58.1M | -14.2x | 0.5x | |
| -$67.1M | n/a | 0.5x | |
| -$73.2M | n/a | 0.5x | |
| -$73.3M | n/a | n/a | |
| -$79.7M | n/a | 0.7x | |
| -$82.0M | n/a | n/a | |
| -$83.2M | -4.4x | 0.4x | |
| -$91.2M | -29.0x | 0.5x | |
| -$97.2M | n/a | 0.7x | |
| -$102M | n/a | n/a | |
| -$104M | -214.7x | n/a | |
| -$183M | -3805.6x | 1.0x | |
| -$192M | n/a | 1.3x | |
| -$212M | -7.1x | 1.3x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies